Profile data is unavailable for this security.
About the company
Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases. The Company is developing non-viral Deoxyribonucleic acid (DNA) technology across four modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit a strong immunological response. The third modality, FixPlas, concerns the application of Imunon’s DNA technology to produce universal cancer vaccines, also called tumor associated antigen cancer vaccines. The fourth modality, IndiPlas, is in the discovery phase and is focused on the development of personalized cancer vaccines, or neoepitope cancer vaccines. Its lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer.
- Revenue in USD (TTM)0.00
- Net income in USD-18.85m
- Incorporated2000
- Employees33.00
- LocationImunon Inc997 Lenox Dr Ste 100LAWRENCEVILLE 08648United StatesUSA
- Phone+1 (609) 896-9100
- Fax+1 (609) 896-2200
- Websitehttps://imunon.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mira Pharmaceuticals Inc | 0.00 | -12.36m | 11.53m | 3.00 | -- | 3.65 | -- | -- | -0.8276 | -0.8276 | 0.00 | 0.2136 | 0.00 | -- | -- | 0.00 | -587.64 | -- | -1,721.90 | -- | -- | -- | -- | -- | -- | -2.63 | 0.00 | -- | -- | -- | -69.77 | -- | -- | -- |
| Kiora Pharmaceuticals Inc | 16.00m | 2.28m | 11.87m | 12.00 | -- | 0.34 | 5.11 | 0.7417 | -1.60 | -1.60 | 1.21 | 1.33 | 0.5427 | -- | 8.64 | 1,333,333.00 | 9.52 | -70.52 | 10.17 | -81.86 | -- | -- | 17.55 | -2,040.61 | -- | -- | 0.00 | -- | -- | -- | 3.97 | -- | -- | -- |
| Pioneer Green Farms Inc | 40.05k | -537.65k | 11.94m | 6.00 | -- | -- | -- | 298.10 | -0.0228 | -0.0228 | 0.0017 | -0.0243 | 0.0664 | 1.01 | -- | 6,675.00 | -89.14 | -- | -- | -- | 26.59 | -- | -1,342.45 | -- | 0.0099 | -155.92 | 14.08 | -- | -- | -- | 35.41 | -- | -- | -- |
| Inhibitor Therapeutics Inc | 0.00 | -3.17m | 12.08m | 3.00 | -- | 2.60 | -- | -- | -0.0184 | -0.0184 | 0.00 | 0.0269 | 0.00 | -- | -- | 0.00 | -34.05 | 27.48 | -34.48 | 32.70 | -- | -- | -- | -- | -- | -- | 0.00 | 0.00 | -- | -- | -125.39 | -- | -- | -- |
| Scorpius Holdings Inc | 9.74m | -32.20m | 12.15m | 82.00 | -- | 0.1584 | -- | 1.25 | -1.22 | -1.40 | 0.3663 | 0.7937 | 0.1372 | -- | 26.56 | 118,815.70 | -47.81 | -39.37 | -58.20 | -43.18 | 68.56 | -- | -348.43 | -1,068.21 | 0.2641 | -198.18 | 0.3179 | -- | 1,789.58 | 3.84 | 1.96 | -- | 27.32 | -- |
| Marizyme Inc | 549.70k | -69.02m | 12.26m | 11.00 | -- | -- | -- | 22.30 | -1.42 | -1.42 | 0.0081 | -0.0822 | 0.0184 | 1.65 | 14.06 | 49,972.73 | -230.68 | -59.02 | -531.63 | -64.47 | 71.17 | 70.38 | -12,555.69 | -9,435.92 | 0.0279 | -0.5837 | 1.92 | -- | 176.59 | 99.98 | -71.22 | -- | -- | -- |
| ELEVAI Labs Inc | 2.18m | -4.62m | 12.30m | 18.00 | -- | 4.54 | -- | 5.63 | -0.2665 | -0.2665 | 0.126 | 0.1435 | -- | -- | -- | 121,351.70 | -- | -- | -- | -- | 67.84 | -- | -211.42 | -- | 1.80 | -- | 0.00 | -- | 123.50 | -- | -138.94 | -- | -- | -- |
| Ayala Pharmaceuticals Inc | 13.00k | -48.07m | 12.39m | 20.00 | -- | -- | -- | 952.77 | -7.46 | -7.46 | 0.0022 | -2.06 | -- | -- | -- | 650.00 | -- | -- | -- | -- | 0.00 | -- | -369,784.60 | -- | -- | -2.31 | -- | -- | -- | -- | -- | -- | -- | -- |
| GlucoTrack Inc | 0.00 | -8.74m | 12.41m | 6.00 | -- | 32.24 | -- | -- | -1.87 | -1.87 | 0.00 | 0.0703 | 0.00 | -- | -- | 0.00 | -520.58 | -94.01 | -2,110.63 | -142.35 | -- | -- | -- | -10,447.96 | -- | -- | 0.3415 | -- | -- | -- | -60.02 | -- | -- | -- |
| Inhibikase Therapeutics Inc | 195.98k | -19.20m | 12.48m | 8.00 | -- | 1.65 | -- | 63.70 | -3.38 | -3.38 | 0.034 | 1.05 | 0.01 | -- | 6.08 | 24,497.50 | -97.88 | -66.49 | -118.76 | -85.55 | -- | -- | -9,797.30 | -1,139.14 | -- | -- | 0.00 | -- | 111.03 | -42.21 | -5.40 | -- | -- | -- |
| Imunon Inc | 0.00 | -18.85m | 12.55m | 33.00 | -- | 1.48 | -- | -- | -2.02 | -2.02 | 0.00 | 0.9041 | 0.00 | -- | -- | 0.00 | -66.82 | -50.18 | -91.53 | -60.27 | -- | -- | -- | -5,725.88 | -- | -- | 0.00 | -- | -100.00 | -- | 45.64 | -- | 26.69 | -- |
| Guardion Health Sciences Inc | 12.06m | -5.12m | 12.89m | 9.00 | -- | 3.78 | -- | 1.07 | -4.00 | -4.00 | 9.49 | 2.66 | 0.9718 | 2.63 | 5.96 | 1,340,280.00 | -41.26 | -77.90 | -47.92 | -86.55 | 43.43 | 42.45 | -42.46 | -176.93 | 6.49 | -4.24 | 0.00 | -- | 10.85 | 67.03 | 101.00 | -- | -58.56 | -- |
| Check Cap Ltd | 0.00 | -17.57m | 12.99m | 85.00 | -- | 0.5484 | -- | -- | -3.00 | -3.00 | 0.00 | 4.05 | 0.00 | -- | -- | -- | -49.87 | -54.23 | -53.46 | -60.24 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 8.06 | -- | -2.46 | -- |
| Dominari Holdings Inc | 3.41m | -24.56m | 13.00m | 26.00 | -- | 0.2727 | -- | 3.82 | -4.64 | -4.64 | 0.6305 | 8.03 | 0.0539 | -- | 0.8023 | 131,000.00 | -38.88 | -26.82 | -39.93 | -27.45 | -- | -- | -721.11 | -3,353.52 | -- | -- | 0.00 | -- | -- | 135.75 | 12.72 | -- | 63.99 | -- |
| Kintara Therapeutics Inc | 0.00 | -9.51m | 13.06m | 2.00 | -- | -- | -- | -- | -4.08 | -4.08 | 0.00 | 0.1071 | 0.00 | -- | -- | 0.00 | -131.55 | -220.94 | -185.60 | -329.97 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 40.24 | -- | 78.93 | -- |
| Nexgel Inc | 4.74m | -3.20m | 13.17m | 19.00 | -- | 2.75 | -- | 2.78 | -0.5535 | -0.5535 | 0.8208 | 0.7688 | 0.4428 | 3.24 | 8.46 | 249,263.20 | -30.72 | -44.61 | -39.92 | -56.19 | 20.14 | 5.02 | -69.38 | -180.98 | 1.41 | -- | 0.1819 | -- | 99.66 | 13.06 | 33.48 | -- | -- | -- |
Data as of Jun 07 2024. Currency figures normalised to Imunon Inc's reporting currency: US Dollar USD
3.56%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Renaissance Technologies LLCas of 31 Mar 2024 | 105.81k | 1.13% |
| Geode Capital Management LLCas of 31 Mar 2024 | 66.60k | 0.71% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 58.22k | 0.62% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 48.81k | 0.52% |
| The Colony Group LLCas of 31 Mar 2024 | 35.00k | 0.37% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 14.30k | 0.15% |
| Tower Research Capital LLCas of 31 Mar 2024 | 4.34k | 0.05% |
| Morgan Stanley & Co. LLCas of 31 Mar 2024 | 1.10k | 0.01% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Mar 2024 | 536.00 | 0.01% |
| M&R Capital Management, Inc.as of 31 Mar 2024 | 333.00 | 0.00% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
